Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Surufatinib with Neoadjuvant Chemo-immunotherapy and CCRT in ESCC
NCT07086469Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jul 2025
- Primary completion
- Jul 2029
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Sun Yat-sen University. Started Jul 2025; status: recruiting.
02
Drugs
surufatinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07086469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086469.